The Health Sciences Authority (HSA) would like to update healthcare professionals on the potential risk of Breast Implant Associated- Anaplastic Large Cell Lymphoma (BIA-ALCL).
HSA has reviewed the available scientific data and global reports of BIA-ALCL and in consultation with our Expert Panel on Breast Implants, we are disseminating this communication to all healthcare professionals. The panel noted that BIA-ALCL occurrences are rare and the associated mortality rates remain low. While regulatory agencies are actively investigating the risk of BIA-ALCL, it is advised that timely detection and appropriate clinical management remain the key factors in managing BIA-ALCL effectively.
Please refer to the Dear Healthcare Professional Letter (DHCPL) below for details:
